[
  {
    "ts": "2026-02-25T08:13:17+00:00",
    "headline": "A Fresh Look At Moderna (MRNA) Valuation After A Sharp Share Price Rebound",
    "summary": "Why Moderna Stock Is Back on Investors’ Radar Moderna (MRNA) has reappeared on many watchlists after a mixed set of signals, including a recent share price near $50.52, positive revenue growth, a sizeable net income loss, and strong recent return figures. See our latest analysis for Moderna. At a share price of $50.52, Moderna has seen sharp recent momentum, with a 15.0% 7 day share price return and 102.0% 90 day share price return. However, the 5 year total shareholder return of a 65.59%...",
    "url": "https://finance.yahoo.com/news/fresh-look-moderna-mrna-valuation-081317235.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "d8eb288d-3ecb-3dc1-9977-e891651bffe0",
      "content": {
        "id": "d8eb288d-3ecb-3dc1-9977-e891651bffe0",
        "contentType": "STORY",
        "title": "A Fresh Look At Moderna (MRNA) Valuation After A Sharp Share Price Rebound",
        "description": "",
        "summary": "Why Moderna Stock Is Back on Investors’ Radar Moderna (MRNA) has reappeared on many watchlists after a mixed set of signals, including a recent share price near $50.52, positive revenue growth, a sizeable net income loss, and strong recent return figures. See our latest analysis for Moderna. At a share price of $50.52, Moderna has seen sharp recent momentum, with a 15.0% 7 day share price return and 102.0% 90 day share price return. However, the 5 year total shareholder return of a 65.59%...",
        "pubDate": "2026-02-25T08:13:17Z",
        "displayTime": "2026-02-25T08:13:17Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/759f0ca28b885d5d534769cdaccce534",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lV6Oo0M_C3X63uXoBkpnwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/759f0ca28b885d5d534769cdaccce534.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KdbFtaQiMRVA6Enl712wNA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/759f0ca28b885d5d534769cdaccce534.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fresh-look-moderna-mrna-valuation-081317235.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fresh-look-moderna-mrna-valuation-081317235.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T14:21:35+00:00",
    "headline": "3 Reasons to Avoid MRNA and 1 Stock to Buy Instead",
    "summary": "What a fantastic six months it’s been for Moderna. Shares of the company have skyrocketed 99.8%, hitting $50.65. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.",
    "url": "https://finance.yahoo.com/news/3-reasons-avoid-mrna-1-142135230.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "91620af7-7266-3659-bba9-bddd2050544a",
      "content": {
        "id": "91620af7-7266-3659-bba9-bddd2050544a",
        "contentType": "STORY",
        "title": "3 Reasons to Avoid MRNA and 1 Stock to Buy Instead",
        "description": "",
        "summary": "What a fantastic six months it’s been for Moderna. Shares of the company have skyrocketed 99.8%, hitting $50.65. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.",
        "pubDate": "2026-02-25T14:21:35Z",
        "displayTime": "2026-02-25T14:21:35Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/7ed68d581c33e574792b9fa0fe3f670c",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "MRNA Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xFZGGzZnWM6N6sCUARtq9w--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/7ed68d581c33e574792b9fa0fe3f670c.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aiku5oDkVhvbobAoAonIcg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/7ed68d581c33e574792b9fa0fe3f670c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/3-reasons-avoid-mrna-1-142135230.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-reasons-avoid-mrna-1-142135230.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T13:35:00+00:00",
    "headline": "Moderna's Ups and Downs: Here's What You Need to Know Before Investing.",
    "summary": "The stock, after a few tough years, soared in the double-digits in January.",
    "url": "https://www.fool.com/investing/2026/02/25/modernas-ups-and-downs-heres-what-you-need-to-know/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "bd32b301-f383-3840-8909-94279fb1c33b",
      "content": {
        "id": "bd32b301-f383-3840-8909-94279fb1c33b",
        "contentType": "STORY",
        "title": "Moderna's Ups and Downs: Here's What You Need to Know Before Investing.",
        "description": "",
        "summary": "The stock, after a few tough years, soared in the double-digits in January.",
        "pubDate": "2026-02-25T13:35:00Z",
        "displayTime": "2026-02-25T13:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/0e4e6459e44865a1aea1ed26dbddd06c",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "An investor studies something on a laptop.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ktn4tgdyg4o_nZ.0_TIfEA--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/0e4e6459e44865a1aea1ed26dbddd06c.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4aEOS0UMPxuXz44AQo7pjw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/0e4e6459e44865a1aea1ed26dbddd06c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/25/modernas-ups-and-downs-heres-what-you-need-to-know/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/modernas-ups-downs-heres-know-133500652.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "INTC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T16:08:32+00:00",
    "headline": "FDA reversal on mRNA-1010 could transform the seasonal influenza vaccines market",
    "summary": "In addition to advancing the seasonal influenza vaccines market, the potential FDA approval of mRNA-1010 will also stake Moderna’s claim in the market.",
    "url": "https://www.clinicaltrialsarena.com/analyst-comment/fda-reversal-mrna-1010-seasonal-influenza-vaccine/",
    "source": "Clinical Trials Arena",
    "provider": "yfinance",
    "raw": {
      "id": "2a20feae-f23e-3a89-a550-44d87f3de98e",
      "content": {
        "id": "2a20feae-f23e-3a89-a550-44d87f3de98e",
        "contentType": "STORY",
        "title": "FDA reversal on mRNA-1010 could transform the seasonal influenza vaccines market",
        "description": "",
        "summary": "In addition to advancing the seasonal influenza vaccines market, the potential FDA approval of mRNA-1010 will also stake Moderna’s claim in the market.",
        "pubDate": "2026-02-25T16:08:32Z",
        "displayTime": "2026-02-25T16:08:32Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/clinical_trials_arena_396/84426a950d402682982ed33b2defa275",
          "originalWidth": 1440,
          "originalHeight": 810,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WXNWt0yUSjXZbIZiXnXZhA--~B/aD04MTA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/84426a950d402682982ed33b2defa275.cf.webp",
              "width": 1440,
              "height": 810,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vcKKuIrC3ROFdMJs63uTqg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/clinical_trials_arena_396/84426a950d402682982ed33b2defa275.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Clinical Trials Arena",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.clinicaltrialsarena.com/analyst-comment/fda-reversal-mrna-1010-seasonal-influenza-vaccine/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fda-reversal-mrna-1010-could-160832497.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]